Dr. Huilai Zhang 张会来
Chief Physician, Associate Professor
Department of Medical Oncology I, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Molecular diagnosis and individualized treatment of malignant lymphoma, with a focus on T-cell lymphoma. Also provides chemotherapy for lung, breast, gastrointestinal, and gynecologic cancers.
Dr. Zhang holds an MD and PhD in Oncology from Tianjin Medical University. Dr. Zhang trained at the Institute of Oncology of Southern Switzerland (IOSI) in 2008 and completed the International Visiting Scholar Program (IVSP) at Moffitt Cancer Center in 2012. With 16 years of clinical experience, Dr. Zhang conducts research on lymphoma and breast cancer.
Name order: in Chinese the family name comes first (Zhang Huilai). Papers usually list the name as Huilai Zhang or Zhang H.
Selected publications
205 papers on PubMed matched by name and affiliation; 62 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Lymphoma Myeloma Leuk, 2026 (senior author): Patient-reported Outcomes in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Glofitamab Plus Gemcitabine and Oxaliplatin in STARGLO. PubMed 42998919
- Am J Hematol, 2026 (senior author): Development and Validation of a Novel Geriatric Risk Score for Prognostication in Older Patients With Hodgkin Lymphoma: A Multicenter Retrospective Study. PubMed 42590970
- Front Immunol, 2026 (senior author): Baseline systemic immune-inflammation index and a novel FLIPI-SII model predict POD24 and long-term survival in grade 1-3a follicular lymphoma. PubMed 42564252
- Front Immunol, 2026 (senior author): Single-cell sequencing uncovers clonal dynamics profiles and therapeutic resistance biomarkers in relapsed and refractory peripheral T-cell lymphoma. PubMed 42500655
- Blood Adv, 2026 (senior author): Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma. PubMed 41824782
- Cancer Biol Med, 2025 (senior author): Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study. PubMed 41025431
- Front Immunol, 2025 (senior author): Correction: Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study. PubMed 40977691
- Hematol Oncol, 2025 (senior author): A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B-Cell Lymphoma of Immune-Privileged Sites. PubMed 40635397
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion